Clinical trials: Mild to Moderate COVID-19
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers, COVID-19
Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19
This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled study to assess the safety, tolerability, and pharmacokinetics (PK) of IGM-6268 administered intranasally and intraorally in healthy volunteers and…
- Trial name
- NCT05184218
- Testing
- IGM-6268
- Where
- South Africa
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- IGM Biosciences, Inc.
Mild to Moderate COVID-19
A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SNS812 in Participants with Mild to Moderate COVID-19
- Trial name
- NCT05941793
- Testing
- MBS-COV
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 135 people
- Sponsor
- Oneness Biotech Co., Ltd.
Mild to Moderate COVID-19
JT001 (VV116) for the Treatment of COVID-19
The purpose of this study is to evaluate the efficacy and safety of JT001 (VV116) in participants with mild to moderate COVID-19.
- Trial name
- NCT05582629
- Testing
- JT001
- Where
- 9 sites in China
- Volunteers
- 1,369 people
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
Infection of Upper Respiratory Tract Caused by 2019-nCoV
SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients
Evaluating the efficacy and safety of SA55 injection in light/medium COVID-19 patients
- Trial name
- NCT06042764
- Testing
- SA55 Injection
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
COVID-19 Respiratory Infection, COVID-19
Efficacy and Safety Study of Essential Oil-Based Preparation Administered to COVID-19 Patients
The aim of this study was to compare the efficacy and safety of the essential oil-based product in patients with mild to moderate symptomatic COVID-19 Positive infection confirmed by PCR.
- Trial name
- NCT06452069
- Testing
- IMMUNO19
- Where
- 10 sites in Turkey (Türkiye)
- Volunteers
- 280 people
- Sponsor
- Biodex S.A
COVID-19
The Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19
This study will assess the safety and efficacy and tolerability of TADIOS compared to placebo in patients with mild to moderate COVID-19.
- Trial name
- NCT05552625
- Testing
- TADIOS
- Where
- 6 sites in India
- Sponsor
- Helixmith Co., Ltd.
COVID-19
A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19
According to In vitro studies, ciclesonide showed good antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04330586
- Testing
- Ciclesonide Metered Dose Inhaler [Alvesco]
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Korea University Guro Hospital
Mild to Moderate COVID-19
Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo
To evaluate the efficacy and safety after administration of DWJ1248 in patients with mild to moderate COVID-19 compared to the placebo.
- Trial name
- NCT04521296
- Testing
- Part 1, Part 2
- Where
- South Korea
- Volunteers
- 432 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Dementia, Dementia, Vascular
Virtual Individual Cognitive Stimulation Therapy: a Proof of Concept Study
Due to COVID-19, the routine treatment for dementia, Cognitive Stimulation Therapy (CST), is currently suspended in multiple countries. Access to treatment is, therefore, paramount.
- Conditions
- Dementia, Dementia, Vascular, Dementia, Mixed, Dementia With Lewy Bodies
- Trial name
- V-iCST (NCT04828434)
- Testing
- Virtual Individual Cognitive Simulation Therapy
- Where
- United Kingdom
- Volunteers
- 34 people
- Sponsor
- University College, London
Covid19
SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease
The 2019 Severe Acute Respiratory Syndrome (SARS) is a global pandemic secondary to a novel coronavirus - SARS-CoV-2. The reported case-fatality ratio for SARS-CoV-2 in the United States is 1.8% with a current death toll of…
- Trial name
- NCT04896606
- Testing
- Standard of Care, SARS-CoV2-CTLS
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- New York Medical College
COVID-19
Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness
The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective in treating mild or moderate COVID-19 illness in adults and adolescents at highest risk for severe outcomes.
- Trial name
- NCT05157243
- Testing
- Nitazoxanide, Vitamin Super-B Complex, Standard of Care
- Sponsor
- Romark Laboratories L.C.
Covid19
Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19
This study is a placebo-controlled, Phase 2a proof-of-concept clinical study which will evaluate efficacy and safety of dalcetrapib in outpatients patients with mild to moderate, symptomatic, confirmed COVID 19.
- Trial name
- NCT04676867
- Testing
- Dalcetrapib
- Where
- Canada
- Volunteers
- 227 people
- Sponsor
- DalCor Pharmaceuticals
Treatment of Covid-19 Virus Infection
Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients
While novel drug discovery and vaccine studies are time taking process, re-purposing old drugs against the COVID-2019 epidemic can help identify treatments, with known pre-clinical, pharmacokinetic, pharmacodynamic, and toxicity…
- Trial name
- NCT04494204
- Testing
- Immunofree tablets and Reginmune capsule
- Where
- 3 sites in India
- Volunteers
- 100 people
- Sponsor
- PUNEET MITTAL
COVID-19
Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk
Few studies have reported the efficacy of HCQ in reducing the viral load and improving the severity of symptoms in hospitalized COVID-19 cases with serious respiratory infection.
- Trial name
- PREVENT (NCT04371926)
- Testing
- Hydroxychloroquine Sulfate
- Sponsor
- Texas Cardiac Arrhythmia Research Foundation
Acupuncture, Covid19
The Effects of Acupuncture in Overcoming Inflammatory Response to COVID-19 Mild-moderate Symptoms
Coronavirus disease 2019 (COVID-19) is a problem that is being faced in more than 200 countries in the world, including Indonesia. The World Health Organization (WHO) has declared the COVID-19 outbreak as a pandemic.
- Trial name
- NCT04844710
- Testing
- acupuncture and standard care, standard care
- Where
- Indonesia
- Volunteers
- 22 people
- Sponsor
- Universitas Indonesia
COVID-19
Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19
AD17002 has demonstrated superior safety and efficacy as a nasal adjuvant function to an influenza vaccine in two completed clinical studies, and has innate immune modulatory and anti-inflammatory properties which could…
- Trial name
- NCT05069610
- Testing
- AD17002
- Where
- 2 sites in Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Advagene Biopharma Co. Ltd.
COVID-19
JINZHEN for Treatment of Mild to Moderate COVID-19
JINZHEN is a botanical drug that contains eight chemical constituents extracted from plant, mineral and animal origin raw materials.
- Trial name
- NCT05092503
- Testing
- JINZHEN Granules for Oral Solution
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Lianyungang Kanion Group, Ltd.
COVID-19
A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
- Trial name
- NCT05689203
- Testing
- QLS1128
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Covid-19
Oral Curcumin, Quercetin and Vitamin D3 Supplements for Mild to Moderate Symptoms of COVID-19
The present study is aimed to investigate the treatment benefits of a combination of dietary supplements quercetin, curcumin and vitamin D3 as add-on therapy to the routine care for early mild symptoms of COVID-19 infection in…
- Trial name
- NCT04603690
- Testing
- Complementary therapy, Standard of care
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Liaquat University of Medical & Health Sciences